Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy.
Combination antiretroviral therapy (cART) has improved survival rates in HIV-infected patients; however, patients now experience comorbidities that require pharmacological intervention, thereby increasing the risk of drug-drug interactions (DDIs). HIV protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and the CCR5 antagonist maraviroc are primarily metabolized via the cytochrome P450 (CYP) system and are prone to pharmacokinetic interactions.(1,2) This article addresses some key challenges that prescribers face when using available drug interaction-data resources in making day-to-day clinical decisions.
Pau
A K
AK
Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. apau@niaid.nih.gov
Boyd
S D
SD
D016907:Adverse Drug Reaction Reporting Systems; D000998:Antiviral Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D002983:Clinical Competence; D004347:Drug Interactions; D004348:Drug Labeling; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D033181:Information Dissemination; D008508:Medication Errors / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D000998:Antiviral Agents